On Invalid Date, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q4 2022 earnings per share (EPS) of -$0.01, up 96.88% year over year. Total Biomarin Pharmaceutical earnings for the quarter were -$249.00 thousand. In the same quarter last year, Biomarin Pharmaceutical's earnings per share (EPS) was -$0.32.
As of Q1 2023, Biomarin Pharmaceutical's earnings has grown year over year. Biomarin Pharmaceutical's earnings in the past year totalled $141.56 million.
What is BMRN's earnings date?
Biomarin Pharmaceutical's earnings date is Invalid Date. Add BMRN to your watchlist to be reminded of BMRN's next earnings announcement.
What was BMRN's revenue last quarter?
On Invalid Date, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q4 2022 revenue of $537.54 million up 19.5% year over year. In the same quarter last year, Biomarin Pharmaceutical's revenue was $449.81 million.
What was BMRN's revenue growth in the past year?
As of Q1 2023, Biomarin Pharmaceutical's revenue has grown 13.53% year over year. This is 48.03 percentage points lower than the US Biotechnology industry revenue growth rate of 61.56%. Biomarin Pharmaceutical's revenue in the past year totalled $2.10 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.